CONTEXT: Young reproductive-age women with irregular menses and androgen excess are at high risk for unfavorable metabolic profile; however, recent data suggest that menstrual regularity and hyperandrogenism improve with aging in affected women approaching menopause. OBJECTIVE: The objective of the study was to determine whether women with hyperandrogenemia (HA) and a history of oligomenorrhea (Oligo) are at an elevated risk for metabolic syndrome (MetS) at the early stages of menopausal transition. METHODS: Baseline data from 2543 participants (mean age of 45.8 yr) in the Study of Women's Health Across the Nation were analyzed. Women with a lifetime history of more than one 3-month interval of nongestational and nonlactational amenorrhea were classified as having a history of Oligo. The highest tertile of serum testosterone was used to define HA. Women with normal serum androgens and eumenorrhea were used as the reference group. Logistic regression models generated adjusted odds ratios (AOR), controlling for age, ethnicity, body mass index, smoking, and study site. RESULTS: Oligo was associated with MetS only when coincident with HA [AOR of 1.93 for Oligo and HA [95% confidence interval (CI) 1.17-3.17], AOR of 1.25 for Oligo and normal androgens (95% CI 0.81-1.93)]. In contrast, HA conferred a consistently significant risk for MetS, regardless of the menstrual frequency status [AOR of 1.48 for HA and eumenorrhea (95% CI 1.15-1.90)]. CONCLUSIONS: Our results suggest that HA but not history of Oligo is independently associated with the risk of prevalent MetS in pre- and perimenopausal women in their 40s.
CONTEXT: Young reproductive-age women with irregular menses and androgen excess are at high risk for unfavorable metabolic profile; however, recent data suggest that menstrual regularity and hyperandrogenism improve with aging in affected women approaching menopause. OBJECTIVE: The objective of the study was to determine whether women with hyperandrogenemia (HA) and a history of oligomenorrhea (Oligo) are at an elevated risk for metabolic syndrome (MetS) at the early stages of menopausal transition. METHODS: Baseline data from 2543 participants (mean age of 45.8 yr) in the Study of Women's Health Across the Nation were analyzed. Women with a lifetime history of more than one 3-month interval of nongestational and nonlactational amenorrhea were classified as having a history of Oligo. The highest tertile of serum testosterone was used to define HA. Women with normal serum androgens and eumenorrhea were used as the reference group. Logistic regression models generated adjusted odds ratios (AOR), controlling for age, ethnicity, body mass index, smoking, and study site. RESULTS: Oligo was associated with MetS only when coincident with HA [AOR of 1.93 for Oligo and HA [95% confidence interval (CI) 1.17-3.17], AOR of 1.25 for Oligo and normal androgens (95% CI 0.81-1.93)]. In contrast, HA conferred a consistently significant risk for MetS, regardless of the menstrual frequency status [AOR of 1.48 for HA and eumenorrhea (95% CI 1.15-1.90)]. CONCLUSIONS: Our results suggest that HA but not history of Oligo is independently associated with the risk of prevalent MetS in pre- and perimenopausal women in their 40s.
Authors: A Katsuki; Y Sumida; E C Gabazza; S Murashima; M Furuta; R Araki-Sasaki; Y Hori; Y Yano; Y Adachi Journal: Diabetes Care Date: 2001-02 Impact factor: 19.112
Authors: Caren G Solomon; Frank B Hu; Andrea Dunaif; Janet E Rich-Edwards; Meir J Stampfer; Walter C Willett; Frank E Speizer; Joann E Manson Journal: J Clin Endocrinol Metab Date: 2002-05 Impact factor: 5.958
Authors: Yong-Woo Park; Shankuan Zhu; Latha Palaniappan; Stanley Heshka; Mercedes R Carnethon; Steven B Heymsfield Journal: Arch Intern Med Date: 2003-02-24
Authors: Sherita Hill Golden; Jingzhong Ding; Moyses Szklo; Maria Ines Schmidt; Bruce B Duncan; Adrian Dobs Journal: Am J Epidemiol Date: 2004-09-15 Impact factor: 4.897
Authors: Qing Peng; Carrie A Karvonen-Gutierrez; John F Randolph; Bin Nan; Daniel McConnell; Siobán D Harlow Journal: J Clin Endocrinol Metab Date: 2019-05-01 Impact factor: 5.958
Authors: Laura C Torchen; Joy N Tsai; Prathima Jasti; Rodrigo Macaya; Ryan Sisk; Matthew L Dapas; M Geoffrey Hayes; Margrit Urbanek; Andrea Dunaif Journal: Obesity (Silver Spring) Date: 2019-11-14 Impact factor: 5.002
Authors: H Maredia; N L Hawley; G Lambert-Messerlian; U Fidow; M S Reupena; T Naseri; S T McGarvey Journal: Am J Hum Biol Date: 2018-04-16 Impact factor: 1.937
Authors: Mira Aubuchon; Ying Liu; Gregory F Petroski; Tom R Thomas; Alex J Polotsky Journal: Syst Biol Reprod Med Date: 2016-05-18 Impact factor: 3.061
Authors: Alex J Polotsky; Amanda A Allshouse; Sybil L Crawford; Sioban D Harlow; Naila Khalil; Rasa Kazlauskaite; Nanette Santoro; Richard S Legro Journal: J Clin Endocrinol Metab Date: 2014-02-11 Impact factor: 5.958
Authors: Alexis N Reeves; Michael R Elliott; Maria M Brooks; Carrie A Karvonen-Gutierrez; Irina Bondarenko; Michelle M Hood; Siobán D Harlow Journal: Ann Epidemiol Date: 2021-02-22 Impact factor: 6.996